Search

A 52-year-old male patient, with metabolic syndrome, Human Immunodeficiency Virus (HIV), insomnia, generalized anxiety disorder, schizophrenia and analgesic medication, who has been suffering from numerous nocturnal episodes of insomnia and restlessness. He had to be rescued by the emergency service when presenting a state of great confusion, agitation and a deep and marked tachycardia. The medication review allows us to associate these adverse events with an excess dose of quetiapine caused by the interaction with darunavir. The intervention consists of informing the doctor of the suspected influence of the interaction of darunavir with quetiapine and proposing the substitution of the antipsychotic for another that uses a different metabolic pathway. Darunavir is expected to increase the plasma concentrations of these antipsychotics, such as quetiapine (CYP3A inhibition). Co-administration of darunavir and quetiapine may be potentially serious as quetiapine-associated toxicity may be increased. The psychiatrist substitutes quetiapine for clotiapine. As of this change in medication, the patient no longer experiences any of the problems that afflicted him, in addition to the fact that he has regained sleep. [ABSTRACT FROM AUTHOR]

Copyright of Kranion is the property of Publicidad Permanyer SLU and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Revista Colombiana de Psiquiatria is the property of Asociacion Colombiana de Psiquiatria and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Revista de Toxicología is the property of Asociacion Espanola de Toxicologia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Corticosteroids are drugs widely used in routine clinical practice that are however associated with neuropsychiatric adverse effects. This paper describes the case of a seventy-one-year man who developed manic symptoms after taking with corticosteroids and was successfully treated with quetiapine and, on the other hand, reviews corticosteroid-induced mania. [ABSTRACT FROM AUTHOR]

Copyright of Biomédica: Revista del Instituto Nacional de Salud is the property of Instituto Nacional de Salud of Colombia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Revista Colombiana de Psiquiatria is the property of Asociacion Colombiana de Psiquiatria and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Revista Colombiana de Psiquiatria is the property of Asociacion Colombiana de Psiquiatria and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Bipolar disorder is considered an important public health problem in the world. The depressive phase is the most important in terms of frequency, duration, and impairment of the quality of life. Common treatment of bipolar depression usually includes antidepressants, mood stabilizers and antipsychotics in different combinations, despite not having a specific indication for that. Quetiapine is the first drug in Europe that has obtained a specific indication for the treatment of bipolar depression, due to a pharmacologic profile that makes it to act on the three neurotransmitter systems involved in bipolar depression neurobiology. Regarding the dopaminergic pathway, quetiapine leads to an increasing of prefrontal dopamine release by antagonism of 5-HT2A receptors, partial agonist of 5-HT1A and antagonism of α2 adrenoceptors. Quetiapine also enhances the serotoninergic transmission by increasing the density of receptors 5-HT1A in the prefrontal cortex and by antagonism of 5-HT2A receptors and α2 adrenoceptors. On the other hand, norquetiapine, the main active metabolite of quetiapine, acts as a 5-HT2C antagonist and is a potent inhibitor of norepinephrine transporter (NET). NET inhibition leads to an increase of noerpinephrine in the synapse, and together with the increase of prefrontal dopamine and serotonin, could explain the antidepressive effect demonstrated by quetiapine in several clinical trials. Quetiapine's action on glutamatergic and GABAergic receptors represents an interesting object of research, together with a potential neuroprotective effect that have already been observed in animal models. [ABSTRACT FROM AUTHOR]

We report a case of Primary Delusional Disorder of Infestation, although most patients reject psychiatric referral and are difficult to engage in medical care, this patient complaint well with medical indications and treatment, probably because the obsessive personality traits. He had mild favorable response to the pharmacological management with quetiapine. [ABSTRACT FROM AUTHOR]

We assessed the efficacy and tolerance of switching to monotherapy with quetiapine fumarate (QF) in treatment-resistant schizophrenia with other antipsychotics, including atypical ones. QF treatment was maintained for 8 weeks. The PANSS scores improved at least 40% over this period. QF was well tolerated without the presence of serious adverse effects. Switching to QF in these patients may therefore be considered as optimal in response and tolerance. [ABSTRACT FROM AUTHOR]

Quetiapine is one of the most used drugs in current Psychiatry, due to its therapeutic efficiency and clinical safety. We report the case of a 26-year-old patient, serious mental retardation due to Y-chromosome partial deletion, that initiates treatment with quetiapine for the control of his aggressiveness, and that develops severe rhabdomyolysis two weeks later. In spite of the clinical safety confirmed of quetiapine, doctors must monitor the appearance of rare but serious adverse effects as the presented one in this clinical case. [ABSTRACT FROM AUTHOR]